Should we be measuring drug levels in pts taking infliximab? ⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO) #ACR21 Abs#1946 #ACRBest @RheumNow https://t.co/sWMen50ljP https://t.co/F4Wpqis3id

• https://bit.ly/3bVdj07

Prospective study of PsO screened @ derm clinics 🔹PsO➕>3 mo back pain starting <45yo➕no biologics➡️rheum ref, 100 pts seen➡️19 dx'ed as: 🔹14 axPsA, 68% met axSpA ASAS, 11/14 w/o pPsA 🔹5 pPsA w/o axial dz https://t.co/azoks5CHCP #ACR21 Abst#1796 @RheumNow

• Early Identification of Psoriatic Arthritis with Axial Involvement Among Patien…

Elevated CRP levels (>3) in PsA associated with ⬆️risk of cardiovascular events ⭐️NSAID use significantly REDUCED risk of CV events Abs#1920 #ACR21 @RheumNow https://t.co/gIz9f4SlWo https://t.co/V4uDeO3Iuz

• https://bit.ly/3n0lLkQ

Racial differences in PsA patients in large US real world database 95% Whites (W) and 5% were AA NSAIDs: 80% W and 78% AAs TNFI: 51% W and 41% of AAs DMARDs: 72% of W and 98% of AAs HTN/DM/Obesity/Gout 🔼 AA Cancer/osteoporosis /anxiety 🔼 whites Abst#1780 #ACR21 @Rheumnow https://t.co/7ee4bVU7ZA

PsO vs PsA patient and disease characteristics COPPAR registry: PsO pts 🔼mean BSA Both 🔼 % of biologic therapy sPGA and PASI 🔼PsO 🔽QOL and physical health in PsA 🔼daily work impairment PsA Abst # 1779 #ACR21 @RheumNow

⭐️Ustekinumab+MTX vs. UST+PBO in PsA? ➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function. *️⃣Thus, no evident to add or maintain ongoing MTX when starting UST Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct

Retrospective cohort study FORWARD databank : ⭐️ 🔼opioid use was associated with higher HAQ-DI and BASDAI scores among patients with PsA or AS Annualized avg opioid use and costs 🔼with 🔼HAQ-DI and BASDAI scores for patients in both cohorts Abst#1117 #ACRBest @RheumNow https://t.co/KB9QUITbAe

*️⃣Abst#1800 observed that a changing pattern of purine, lipid, & amino acid metabolites occurred during transition from PsO to PsA. *️⃣Compared to pts w/ Pso that didn't progress to PsA, those that progressed had elevated levels of guanine! Potential biomarkers? #ACR21 @RheumNow https://t.co/iQh1ZapDMB

⭐️Immune phenotyping of 45 patients with Pso and 41 PsA pts showed a number of cell subsets significantly different in Pso vs PsA ⭐️Future possibility of using a combination of selected immune cell subsets as a method for detecting PsA in Pso pts Abst#1774 #ACR21 @Rheumnow https://t.co/ER1MPOvMa6

Abst#1774 identified a blood-based immune profile with a machine-learning approach that discriminates PsA from Pso. ➡️↑ proportions of differentiated CD4+CD196+CD183–CD194+ and CD4+CD196–CD183–CD194+ T-cells in PsA #ACR21 @RheumNow https://t.co/64uhJCd2qo

#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK

• Olga Petryna on Twitter: &quot;Abst1773 #ACR21 @rheumnow guselkumab outperforms…